Journal: iScience

Article Title: The CD49b (ITGA2) collagen receptor excludes CD8 + T cell infiltration in pancreatic ductal adenocarcinoma

doi: 10.1016/j.isci.2026.116500

Figure Lengend Snippet: Targeting CD49b delays the tumor growth in vivo (A) Representative images of human PDAC cell lines cultured on COLI or COLIV-coated plates, with or without vatelizumab (10 μg/mL), following a 2-h incubation. (B) Representative images of mouse KPC cells treated with or without vatelizumab (10 μg/mL) compared to anti mouse-CD49b antibody (10 μg/mL) on COL I and COL IV coated substrates, following a 2-h incubation. Scale bars, 600 μm. (C) Histogram showing human CD49b expression in KPC wt and KPC 49bKO . (D) Representative images of mouse KPC cells expressing human CD49b treated with or without vatelizumab (10 μg/mL) on COL I- and COL IV-coated substrates after 2-h incubation. Scale bars, 600 μm. (E) C57BL/6J mice were subcutaneously inoculated with KPC 49bKOhCD4b cells (1 × 10 6 cells). Tumors were allowed to grow before mice were randomly assigned to PBS or vatelizumab (200 μg) intratumoral treatment groups. Tumor growth was measured three times per week. (F) Bar graph shows immune cell infiltration in tumors, (G) C57BL/6J mice were subcutaneously inoculated with KPC wt cells (1 × 1 6 cells) on the right flank. Mice were randomly grouped to IgG control or amCD49b (200 μg) intratumoral treatment groups. Tumor growth was measured three times per week. (H) Bar graph shows immune cell infiltration in tumors. Statistical significance: (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001). Data are shown as mean ± SEM.

Article Snippet: The treatment group received intratumoral injections of Vatelizumab (GBR500, MedChemExpress HY-P99524) at 200 μg per tumor, administered three consecutive times.

Techniques: In Vivo, Cell Culture, Incubation, Expressing, Control